SESenar Ebinç

Senar Ebinç

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Senar Ebinç has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Prognostic Value of the Advanced Lung Cancer Inflammation Index on Disease-Free Survival in Patients with Gastric Cancer Receiving Neoadjuvant Chemotherapy

    by Mahmut Kara, Muslih Ürün, Senar Ebinç, Yasin Sezgin, Yonca Yılmaz Ürün, Mehmet Naci Aldemir

    Objectives: The present study investigated whether the pre-treatment Advanced Lung Cancer Inflammation Index (ALI) could serve as a prognostic indicator of disease-free survival (DFS) in patients with locally advanced gastric cancer treated with neoadjuvant chemotherapy followed by curative D2 gastrectomy. Methods: We retrospectively analyzed 157 patients with gastric adenocarcinoma who received treatment between 2016 and 2025. The pre-treatment ALI was derived from body mass index, serum albumin concentration, and the neutrophil-to-lymphocyte ratio. The association of clinical and laboratory variables with DFS was assessed using Kaplan–Meier survival analysis and Cox proportional hazards regression. Results: Median patient age was 63.6 years (61.1% male). Overall, 50.3% of patients experienced recurrence. Multivariate analysis demonstrated that ALI is an independent prognostic factor for DFS (HR = 0.867; 95% CI: 0.768–0.978; p = 0.020). Advanced age (p = 0.040), advanced clinical N stage (p < 0.001), and non-FLOT regimens (p = 0.003) also significantly predicted poorer DFS. Kaplan–Meier analysis confirmed that median DFS was significantly shorter in the low ALI group (38.9 months) compared to the high ALI group (52.0 months; p = 0.029). Conclusions: A low pre-treatment ALI score independently predicts shorter DFS in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy and surgery. ALI serves as an accessible, low-cost biomarker to identify high-risk patients, warranting further prospective validation.

  • Open Access

    Adjuvant chemotherapy patterns and clinicopathological factors associated with survival in patients aged 70 years and older with resected stage II–III colon cancer: a single-center real-world study

    by Zekeriya Hannarici, Aykut Turhan, Mehmet Emin Büyükbayram, Senar Ebinç, Alperen Akansel Çağlar, Mehmet Bilici, Salim Başol Tekin

    Aims: Older adults are underrepresented in adjuvant colon cancer trials, leaving uncertainty regarding oxaliplatin benefit and optimal treatment duration. This study evaluated the associations of adjuvant chemotherapy patterns, treatment duration, and clinicopathological factors with overall survival (OS) and disease-free survival (DFS) in patients aged ≥70 years with resected stage II-III colon cancer.Methods: This single-center retrospective study included patients aged ≥70 years with resected stage II-III colon cancer. Survival outcomes were analyzed using Kaplan-Meier methods and Cox regression analyses.Results: Forty-six patients were included; the mean age was 74.39±4.48 years, and 56.5% were male. Overall, 56.5% received oxaliplatin-containing chemotherapy, and 71.7% completed six months of treatment. Disease progression occurred in 41.3% of patients, and 28.3% died. Estimated mean OS and DFS were 100.9 months and 84.2 months, respectively. Although six-month chemotherapy was associated with OS and showed a borderline association with DFS in reduced exploratory Cox models, these associations were attenuated and were no longer statistically significant in the 6-month landmark sensitivity analysis. Oxaliplatin-containing chemotherapy was not significantly associated with OS or DFS in the overall cohort. Conclusion: In this retrospective single-center cohort of patients aged ≥70 years with resected stage II–III colon cancer, sixmonth adjuvant chemotherapy was associated with longer survival in conventional analyses but was no longer statistically significant in the 6-month landmark sensitivity analyses. Therefore, this finding should be interpreted cautiously because of potential immortal time bias, survivor selection, treatment-selection bias, and residual confounding. Oxaliplatin-containing chemotherapy was not significantly associated with OS or DFS in the overall cohort. These findings should be considered hypothesis-generating and should not be interpreted as causal evidence regarding optimal treatment duration or oxaliplatin benefit in older adults.

  • Open Access

    Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    by Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Asik, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gulhan Dinc, et al.

    Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by substantial biological heterogeneity and variable clinical outcomes. Reliable prognostic tools are needed to improve risk stratification following neoadjuvant chemotherapy (NACT). This study aimed to evaluate the association of the Clinical–Pathologic Stage, Estrogen/Grade (CPS-EG) score with pathological complete response (pCR) and survival outcomes in patients with locally advanced TNBC treated with NACT. Methods: In this multicenter retrospective cohort study, 690 patients with locally advanced TNBC treated with NACT between 2010 and 2024 at 25 oncology centers were included. Patients were categorized according to CPS-EG score (≤3 vs. >3). Associations between CPS-EG score, clinicopathological characteristics, pCR, disease-free survival (DFS), and overall survival (OS) were analyzed. Survival outcomes were evaluated using Kaplan–Meier and Cox regression analyses. Results: Patients with a CPS-EG score > 3 had significantly lower pCR rates and higher recurrence rates compared with those with a CPS-EG score ≤ 3 (p < 0.001 for both). Five-year OS rates were 83.7% and 54.1% in the CPS-EG ≤ 3 and > 3 groups, respectively, while the corresponding five-year DFS rates were 76.4% and 51.9% (p < 0.001 for both). In the multivariable analysis, CPS-EG > 3 remained independently associated with worse OS (HR 1.46, 95% CI 1.08–1.98, p = 0.015) and DFS (HR 1.73, 95% CI 1.26–2.38, p < 0.001). Conclusions: A higher CPS-EG score is associated with a lower likelihood of achieving pCR and poorer long-term survival outcomes in patients with locally advanced TNBC treated with NACT. The CPS-EG score represents a simple and readily available tool that may support risk stratification and clinical decision-making in routine practice.

  • Open Access

    Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study

    by Ahmet Unlu, Asim Armagan Aydin, Esra Sazimet Kars, Ozden Ozturk, Mehmet Acun, Mehmet Nuri Baser, Mahmut Kara, Sati Sena Coraoglu, Nurbanu Inci, Muhammet Ali Kaplan, et al.

    Background: Reliable biomarkers that capture tumor–host interactions and predict treatment resistance in extensive-stage small cell lung cancer (SCLC) remain limited. We evaluated the prognostic and predictive value of the pretreatment lactate dehydrogenase-to-albumin ratio (LAR), an integrative biomarker reflecting metabolic activity, systemic inflammation, and host nutritional status. Methods: This multicenter, retrospective cohort study included patients with extensive-stage SCLC treated at five tertiary centers between 2016 and 2024. Pretreatment LAR was calculated using baseline serum lactate dehydrogenase and albumin levels and dichotomized using a Youden index-derived cut-off at the 12-month overall survival (OS) horizon. Time-dependent receiver operating characteristic (ROC) analyses using inverse probability weighting were performed to assess discriminative performance. Survival outcomes were evaluated using Kaplan–Meier estimates and Cox proportional hazards models. Associations with platinum resistance and lack of objective treatment benefit (defined as progressive disease as best response) were examined using logistic regression models. Results: A total of 223 patients were included. Elevated LAR was associated with inferior OS (median, 15.8 vs. 25.2 months; log-rank p < 0.001) and progression-free survival (7.9 vs. 11.5 months; p < 0.001). In multivariable analysis, LAR remained independently associated with OS (HR, 1.43; 95% CI, 1.04–1.95; p = 0.028). LAR demonstrated modest but consistently superior discriminative performance compared with other inflammatory indices for both 12-month OS (area under the curve [AUC], 0.692) and 6-month progression-free survival (PFS) (AUC, 0.646), with statistically significant differences in DeLong comparisons. Higher LAR was independently associated with increased odds of platinum resistance (adjusted odds ratio [aOR], 2.31; 95% CI, 1.41–3.81; p = 0.001) and lack of objective treatment benefit (adjusted OR, 2.04; 95% CI, 1.33–3.14; p = 0.001). Conclusions: Pretreatment LAR is a clinically accessible and biologically integrative biomarker associated with survival and treatment resistance in extensive-stage SCLC. By capturing tumor–host interactions, LAR may support risk stratification and identify patients at increased risk of early treatment failure. Prospective validation is warranted to define its role in biomarker-driven clinical decision-making.


  • Open Access

    Glasgow prognostic score as a predictor of adjuvant nivolumab efficacy in esophageal squamous cell carcinoma

    by Mahmut Kara, Senar Ebinç, Yasin Sezgin, Muslih Ürün, Mehmet Naci Aldemir

    Adjuvant nivolumab is standard for locally advanced esophageal cancer patients without pathological complete response after neoadjuvant chemoradiotherapy, and this study evaluated its efficacy and the predictive value of the Glasgow Prognostic Score on survival. We retrospectively analyzed 33 patients diagnosed with stage II-III esophageal squamous cell carcinoma (ESCC) who were followed at our center between January 2020 and January 2025. These patients had undergone neoadjuvant chemoradiotherapy followed by R0 resection yet exhibited residual disease (ypT1-4 or ypN+). The relationship between disease-free survival (DFS) and overall survival (OS) and GPS (0,1,2) was analyzed. Our study shows that adjuvant nivolumab is effective in ESCC, with superior responses in patients with low Glasgow Prognostic Score and markedly reduced benefit in those with high GPS. Mean DFS was 43.2 months in GPS 0 patients (median not reached), compared with median DFS of 12 and 5 months in the GPS 1 and GPS 2 groups, respectively. Mean OS in the GPS 0 group was 49.5 months (median not reached), while median OS decreased to 27 months in GPS 1 and 10 months in GPS 2 patients. Adjuvant nivolumab improves survival in locally advanced ESCC with residual disease. Lower Glasgow Prognostic Score is associated with improved DFS and OS, underscoring the role of systemic inflammation in immunotherapy response. GPS may be a simple and cost-effective predictive biomarker for adjuvant immunotherapy.

  • Open Access

    Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study

    by Zekeriya Hannarici, Aykut Turhan, Mehmet Emin Buyukbayram, Alperen Akansel Çağlar, Mehmet Bilici, Salim Başol Tekin, Senar Ebinç, Ali Yılmaz, Birol Ocak, Pınar Çoban Eşdur, et al.

    Background: Finding dependable prognostic biomarkers for metastatic colorectal cancer (mCRC) is crucial. The albumin-to-carcinoembryonic antigen (CEA) ratio (ACR), a measure of nutritional-inflammatory status and tumor load, has emerged as a promising prognostic indicator. This study assessed ACR’s prognostic value of ACR in patients with mCRC. Methods: This retrospective study included 125 patients with mCRC followed at our institution between July 2010 and March 2022. ROC curve analysis was used to determine the optimal cutoff values for ACR, prognostic nutritional index (PNI), lymphocyte-to-monocyte ratio (LMR), and CEA. Kaplan–Meier and Cox regression analyses were used to evaluate progression-free survival (PFS) and overall survival (OS). Results: PFS and OS were 13.3 and 26.0 months, respectively. Patients with an ACR ≥ 4.24 experienced significantly longer PFS (16.8 vs. 11.0 months; p = 0.001) and OS (32.0 vs. 22.3 months; p < 0.001) compared with those with ACR < 4.24. In univariable analyses, ACR was significantly associated with both PFS and OS, whereas PNI, LMR, and CEA were associated with OS only. In multivariable Cox regression models ACR showed a significant association with both PFS (HR 0.413; 95% CI: 0.265–0.643; p < 0.001) and OS (HR 0.341; 95% CI: 0.210–0.551; p < 0.001), while maintenance therapy was significantly associated with PFS only and ECOG performance status, LMR and PNI with OS only. Conclusions: ACR appears to be a cost-effective biomarker that is associated with PFS and OS in mCRC. These findings suggest that ACR may have potential value for prognostic assessment and risk stratification in patients with mCRC.


  • Evaluation of demographic and clinical data of patients diagnosed with lung cancer: a single-center experience

    by Mehmet Maruf Kayran, Mehmet Naci Aldemir, Ozan Aydemir, Mehmet Erdem, Şerafettin Erzen, Senar Ebinç

    Aims: To retrospectively evaluate the demographic, epidemiological, and clinical characteristics of patients diagnosed with lung cancer. Methods: Patients diagnosed and treated for lung cancer in our medical oncology clinic were included in the study. Patient records were obtained retrospectively from the electronic databases of the hospital. Demographic and clinical characteristics were recorded for each patient. Results: A total of 313 patients diagnosed with lung cancer were included in the study. Mean age was 62.7 ± 10.3 years. Of the patients, 83.4% were male and 16.6% were female. Most common presenting complaints were dyspnea (40.9%) and chest pain (32.2%). Smoking history was present in 66.5% of patients, and 15.3% had a history of tandoori smoke exposure. Radiologically, the most frequent tumor localization was the right upper lobe (38%). Most common histopathological types were squamous cell carcinoma (39.3%), adenocarcinoma (27.2%), and small cell carcinoma (20.1%). Most common disease stage at the time of diagnosis was stage IV (48.9%), followed by stage III (39%), II (10.9%), and I (1.3%). Mean OS was 14 ± 1.4 (range, 11.2–16.8) months. Higher ECOG performance scores and advanced stage were associated with poorer survival. Mean OS was 31 months for females and 13 months for males. Conclusion: The findings obtained in our study were found to be consistent with those of previous research. In Turkey, the high prevalence of smoking, the asymptomatic nature of the disease, and the tendency of patients to attribute existing symptoms to smoking appear to contribute to delayed presentation to healthcare facilities, which likely plays a role in the high proportion of advanced-stage diagnoses. Additionally, unlike in other studies, the higher proportion of female patients diagnosed in our cohort was considered to be related to the widespread use of tandoori ovens in our region.

  • Open Access

    Prognostic Value of the CPS-EG Score in Locally Advanced Triple-Negative Breast Cancer: A Multicenter Retrospective Cohort Study

    by Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, et al.

    Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis. Effective prognostic tools are essential to guide risk-adapted strategies following neoadjuvant chemotherapy (NACT). In this multicenter retrospective study, we evaluated 690 patients with locally advanced TNBC treated between 2010 and 2023 across 25 oncology centers. Patients were stratified into CPS-EG risk groups: low (0–1), intermediate (2–3), and high (≥4). The CPS-EG score was strongly associated with pathological complete response (pCR), recurrence, disease-free survival (DFS), and overall survival (OS). Five-year DFS rates were 80.6%, 53.2%, and 31.5% in the low-, intermediate-, and high-risk groups, respectively, while OS rates were 76.7%, 53.2%, and 48.8% (p<0.001). Multivariate analysis confirmed CPS-EG as an independent predictor of both DFS and OS after adjusting for clinicopathological factors. These findings highlight the CPS-EG score as a simple, cost-effective, and widely applicable prognostic tool that may improve post-NACT risk stratification and support treatment decisions, especially in resource-limited oncology settings.

  • Open Access

    Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638

    by Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, et al.

    In the original publication, there was a mistake in Figure 2 as published

  • Open Access

    Evaluation of cardiovascular, bone mineral, and hematological disorders in chronic hemodialysis patients

    by Bahar Özgül, Ozan Aydemir, Mehmet Erdem, Emrah Elis, Senar Ebinç

    Aims: The prevalence of cardiovascular diseases, bone mineral disorders, and anemia in patients undergoing continuous hemodialysis is higher than in the normal population. In addition, due to the ongoing renal parenchymal loss in these patients, there is continuous deterioration in bone mineral metabolism. Anemia, a leading hematological disorder, is considered to be one of the most important and frequent complications leading to compromised quality of life. In this study, we aimed to investigate cardiovascular, bone mineral, and hematological disorders in patients undergoing continuous hemodialysis. Methods: Clinical data of 56 patients receiving continuous hemodialysis at Yüzüncü Yıl University Faculty of Medicine Hospital Nephrology Clinic Dialysis Unit between 01.07.2021 and 01.07.2022 were evaluated retrospectively. Echocardiography), dual-energy X-Ray absorptiometry and laboratory parameters were evaluated for each patient. Demographic characteristics and medications were recorded. Due to the retrospective nature of the study, the sample size was not calculated. Results: The study included 56 patients undergoing hemodialysis, comprising 26 (46.4%) men and 30 (53.6%) women. Mean duration of hemodialysis was 5.55±5.09 years. Moreover, 92.9% of the patients were receiving medications, with the most common medications including erythropoiesis-stimulating agents (69.6%), phosphorus binders (48.2%), iron supplements (28.6%), active vitamin D supplements (37.5%), and cinacalcet (12.5%). Cardiovascular diseases were detected in 60.7% of the patients, osteoporosis in 41.1%, and anemia in 78.6%. Conclusion: Cardiovascular disease, bone mineral disorders, and hematological disorders are commonly seen in hemodialysis patients. Hemodialysis patients should be regularly evaluated for complications.